for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

13.00USD

Change

0.00(0.00%)

Volume

3,557

Today's Range

13.00

 - 

13.00

52 Week Range

11.51

 - 

43.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.00
Open
13.00
Volume
3,557
3M AVG Volume
16.36
Today's High
13.00
Today's Low
13.00
52 Week High
43.85
52 Week Low
11.51
Shares Out (MIL)
53.76
Market Cap (MIL)
667.14
Forward P/E
-2.12
Dividend (Yield %)
--

Latest Developments

More

Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS 2019

Atara Biotherapeutics Reports Q2 Loss Per Share $1.60

Atara Biotherapeutics Announces Pricing Of $150 Mln Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Industry

Biotechnology & Drugs

Contact Info

611 Gateway Blvd Ste 900

+1.650.2788930

http://www.atarabio.com/

Executive Leadership

Pascal Touchon

President, Chief Executive Officer, Director

Utpal Koppikar

Chief Financial Officer

Joseph Newell

Executive Vice President, Chief Technical Operations Officer

Mina Kim

Senior Vice President, General Counsel, Secretary

Derrell D. Porter

Senior Vice President,Head of Commercial

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.750

2017

-4.000

2018

-5.270

2019(E)

-5.856
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.16
Return on Equity (TTM)
-72.75

Latest News

Latest News

BRIEF-Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer

* ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING Source text (http://bit.ly/2CKPbcB) Further company coverage:

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

BRIEF-Atara Biotherapeutics reports Q3 loss per share $1.02

* Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights

BRIEF-Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230

* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations

* Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS)

BRIEF-Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

* Atara Biotherapeutics Inc - announced receipt of positive regulatory feedback from Health Canada for ATA129

BRIEF-Atara Biotherapeutics receives FDA orphan drug designation for ATA230

* Atara Biotherapeutics receives FDA orphan drug designation for ata230

BRIEF-Atara Biotherapeutics reports Q2 loss per share of $0.94

* Atara biotherapeutics announces second quarter 2017 financial results and recent highlights

BRIEF-Atara Biotherapeutics reports Q1 loss per share $0.88

* Atara Biotherapeutics announces first quarter 2017 financial results and recent highlights

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up